Actinium Pharmaceuticals, Inc.
ATNM
$1.52
-$0.03-1.94%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | 81.00K | 81.00K | 81.00K |
| Total Revenue | -- | -- | 81.00K | 81.00K | 81.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 81.00K | 81.00K | 81.00K |
| SG&A Expenses | 18.05M | 12.08M | 11.69M | 11.59M | 12.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.16M | 42.12M | 45.04M | 46.79M | 50.01M |
| Operating Income | -49.16M | -42.12M | -44.96M | -46.71M | -49.93M |
| Income Before Tax | -45.51M | -38.24M | -40.92M | -42.62M | -46.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.51 | -38.24 | -40.92 | -42.62 | -46.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.51M | -38.24M | -40.92M | -42.62M | -46.45M |
| EBIT | -49.16M | -42.12M | -44.96M | -46.71M | -49.93M |
| EBITDA | -48.51M | -41.46M | -44.30M | -46.05M | -49.26M |
| EPS Basic | -1.47 | -1.27 | -1.40 | -1.52 | -1.72 |
| Normalized Basic EPS | -0.92 | -0.80 | -0.88 | -0.95 | -1.08 |
| EPS Diluted | -1.47 | -1.27 | -1.40 | -1.52 | -1.72 |
| Normalized Diluted EPS | -0.92 | -0.80 | -0.88 | -0.95 | -1.08 |
| Average Basic Shares Outstanding | 123.57M | 120.27M | 116.49M | 112.48M | 108.59M |
| Average Diluted Shares Outstanding | 123.57M | 120.27M | 116.49M | 112.48M | 108.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |